Why the study?
Does Org 6001 differ from lignocaine in its electrophysiological effects on human ventricular muscle in vitro?
Population
Human ventricular muscle in vitro
Comparison
Org 6001 (4 to 16 mg/l) vs Lignocaine (4 to 16 mg/l)
Design
Preclinical
Authors
Loading...
Electrophysiological differences suggest caution against assuming equivalent antiarrhythmic action; leaves open whether Org 6001 is superior in arrhythmia models.
Does Org 6001 differ from lignocaine in its electrophysiological effects on human ventricular muscle in vitro?
Org 6001 and lignocaine, both class 1 antidysrhythmic drugs, exhibit distinct electrophysiological profiles on human ventricular muscle in vitro, with Org 6001 showing greater potency in reducing the maximum rate of depolarization without prolonging the absolute refractory period.
Kathleen A. Kane (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: